Abstract
Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human 4-1BB, to restrict the 4-1BB stimulation in tumors. B7-H3×m4-1BB elicited a 4-1BB–dependent antitumor response in hB7-H3–overexpressing tumor models without systemic toxicity. BsAb primarily targets CD8 T cells in the tumor and increases their proliferation and cytokine production. Among the CD8 T cell population in the tumor, 4-1BB is solely expressed on PD-1
Expert Insight: New for NanoDrop: 21 CFR part 11 & distinguishing DNA from RNA: Your questions answered
Watch this on-demand webinar to learn more about new updates of the NanoDrop One platform
14 Dec 2020
Patrick Brown, NanoDrop Thermo Fisher Scientific
This year, the NanoDrop One spectrophotometer has received two major updates – features that allow 21 CFR Part 11 compliance and the ability to distinguish DNA from RNA.
In this on-demand SelectScience webinar, Patrick Brown, product manager at NanoDrop Thermo Fisher Scientific, explores how electronic signatures, audit trails, and user account access have been incorporated into the NanoDrop One platform using the Thermo Scientific Security Suite software. Also, hear about how the Thermo Scientific Acclaro Sample Intelligence Technology algorithms have been updated to identify RNA contamination in DNA and DNA contamination in RNA.